Kyowa Kirin mogamulizumab data show survival gains in rare CTCL
Kyowa Kirin has presented two indirect treatment comparison (ITC) analyses suggesting its monoclonal antibody mogamulizumab (POTELIGEO) is associated with substantially improved overall survival compared with standard of care in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), two rare subtypes of cutaneous T-cell lymphoma (CTCL). The findings were disclosed at the World Congress of Cutaneous Lymphoma 2026 on 30 June.
Both analyses drew on patient-level data from the mogamulizumab arm of the Phase 3 MAVORIC trial, cross-referenced against separate real-world registry datasets from Australia and Denmark. The exercise was designed to address a known weakness in MAVORIC itself: a high crossover rate between treatment arms that prevented direct assessment of overall survival at the time of the original trial readout.
The data in detail
In the Australian analysis, led by researchers at the Peter MacCallum Cancer Centre in Melbourne, mogamulizumab was compared against vorinostat in 67 patients drawn from a single-centre database. Median overall survival was not reached in the mogamulizumab cohort, against 31.0 months for the vorinostat group. The hazard ratio for death was 0.48 (95% CI: 0.30 to 0.76; p=0.002), indicating a statistically significant 52% relative reduction in mortality risk. A numerically longer time to next treatment was also recorded for mogamulizumab (9.13 months versus 5.82 months), though this result did not reach statistical significance.
The Danish analysis used national registry data covering 209 patients on standard of care between 1996 and 2024. Again, median OS was not reached with mogamulizumab. Patients on standard of care had a median OS of 17.0 months. The hazard ratio of 0.38 (95% CI: 0.25 to 0.59; p less than 0.001) was the more pronounced of the two, though the authors noted that the Danish cohort spans nearly three decades and therefore encompasses considerable variation in treatment practice and disease management.
Professor H. Miles Prince, principal investigator at Peter MacCallum Cancer Centre, said that indirect treatment comparisons "help to bridge critical evidence gaps in MF and SS, giving clinicians a clearer picture of long-term outcomes in real-world practice."
Market and regulatory context
CTCL is a chronic, often treatment-refractory malignancy with a small global patient population, and the evidence base for systemic therapies remains thinner than in more prevalent haematological cancers. Mogamulizumab targets CCR4, a chemokine receptor expressed on malignant T cells, and received FDA approval in 2018 for adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy. The drug is marketed in the US as POTELIGEO.
The use of ITC methodology, which integrates clinical trial and real-world data to estimate comparative effects in the absence of head-to-head trial data, is increasingly accepted by health technology assessment bodies in Europe and elsewhere. Kyowa Kirin's own framing of the analyses as addressing "evidence gaps that limit access in some countries" is a signal that the data are intended to support reimbursement submissions in markets where direct comparative OS data were previously absent.
The retrospective design of both studies and the long time horizon of the Danish registry are the most substantive limitations flagged by the investigators. Differences in supportive care standards between the trial era and the real-world observation windows could confound the survival estimates. Clinicians and payers considering these data will likely request sensitivity analyses and longer follow-up from the real-world cohorts before updating treatment guidelines or coverage decisions.